 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- rontalizumab (RG7415) / Roche, sifalimumab (MDX-1103) / AstraZeneca, Saphnelo (anifrolumab) / AstraZeneca
Targeting Type I IFN in SLE and lupus nephritis (Concert Hall) - Feb 25, 2024 - Abstract #LUPUS2024LUPUS_45;
The anifrolumab program reaffirmed the clinical significance of type I IFN in SLE and boosted confidence that other approaches to inhibit type I IFN would prove efficacious. This presentation will review various strategies being pursued in order to block the interferon pathway in SLE and lupus nephritis.
- | Saphnelo (anifrolumab) / AstraZeneca
Journal: Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations. (Pubmed Central) - Aug 21, 2021
Anifrolumab, a human monoclonal antibody against the type I IFN receptor, has recently been evaluated in two Phase III clinical trials for the treatment of moderate-to-severe SLE. Here, we review the clinical efficacy and safety of anifrolumab and discuss the potential challenges in determining the optimal SLE patient subgroup for treatment.
- | rontalizumab (RG7415) / Roche, sifalimumab (MDX-1103) / AstraZeneca
Journal: S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases. (Pubmed Central) - Mar 23, 2021
Together, our results show that S95021 is a new potent, selective and pan IFN-α-neutralizing mAb. It is currently further evaluated as a valid therapeutic candidate in selected autoimmune diseases in which the IFN-α pro-inflammatory pathway is dysregulated.
- Stelara (ustekinumab) / J&J, Epratucyn (epratuzumab) / Gilead
[VIRTUAL] Efficacy of Biological Agents for the Management of Systemic Lupus Erythematosus: A Systematic Review and Network Meta-Analysis () - Feb 21, 2021 - Abstract #CRAAHPA2021CRA-AHPA_135;
This systematic review identified that there was heterogeneity in the outcome measures and endpoints used. In the future, the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach will be applied to rate the quality of the evidence, and to gain insight into methodological pitfalls that could have negatively altered the results of RCTs.
- || rontalizumab (RG7415) / Roche
Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (clinicaltrials.gov) - Aug 13, 2016
P2, N=238, Completed, Sponsor: Genentech, Inc.
In the future, the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach will be applied to rate the quality of the evidence, and to gain insight into methodological pitfalls that could have negatively altered the results of RCTs. Trial primary completion date: Aug 2013 --> Jan 2012
- |||| rontalizumab (RG7415) / Roche
Trial completion: A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 8, 2013
P2, N=238, Completed, Sponsor: Genentech
Trial primary completion date: Aug 2013 --> Jan 2012 Active, not recruiting --> Completed